 |
Video: What is a Stock Split?
|
 |
Genetic Technologies is a molecular diagnostics company that provides predictive testing and assessment tools to help physicians manage women's health. Co.'s key product, BREVAGenplus, was a clinically validated risk assessment test for non-hereditary breast cancer. Co. has launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. Co. has developed two new cancer risk assessment tests branded as GeneType for Colorectal Cancer and GeneType for Breast Cancer. Co. also develops other risk assessment tests across a range of diseases, including cardiovascular disease, type 2 diabetes, prostate cancer and melanoma. According to our GENE split history records, Genetic Technologies has had 3 splits. | |
 |

Genetic Technologies (GENE) has 3 splits in our GENE split history database. The first split for GENE took place on January 20, 2015. This was a 1 for 5 reverse split, meaning for each 5 shares of GENE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 200 share position following the split. GENE's second split took place on August 15, 2019. This was a 1 for 4 reverse split, meaning for each 4 shares of GENE owned pre-split, the shareholder now owned 1 share. For example, a 200 share position pre-split, became a 50 share position following the split. GENE's third split took place on December 14, 2023. This was a 1 for 5 reverse split, meaning for each 5 shares of GENE owned pre-split, the shareholder now owned 1 share. For example, a 50 share position pre-split, became a 10 share position following the split.
When a company such as Genetic Technologies conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the GENE split history from start to finish, an original position size of 1000 shares would have turned into 10 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Genetic Technologies shares, starting with a $10,000 purchase of GENE, presented on a split-history-adjusted basis factoring in the complete GENE split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/17/2015 |
|
End date: |
12/27/2024 |
|
Start price/share: |
$188.80 |
|
End price/share: |
$0.77 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.59% |
|
Average Annual Total Return: |
-42.75% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$40.76 |
|
Years: |
9.87 |
|
|
 |
Date |
Ratio |
01/20/2015 | 1 for 5 | 08/15/2019 | 1 for 4 | 12/14/2023 | 1 for 5 |
|
 |